Abstract: Methods for modification of abnormal protein interactions manifested as excessive PACT-mediated PKR activation within cells are described. Methods include administration of luteolin to cells that exhibit dysregulation in PACT-mediated PKR activation. Methods can decrease or prevent excessive non-viral PACT-mediated PKR activation in a cell as may occur due to expression by the cell of a mutant PACT protein. Methods can decrease an abnormal prolonged stress response as may occur in the absence of a stress-inducing activity or agent.

Abstract: Methods for modification of abnormal protein interactions manifested as excessive PACT-mediated PKR activation within cells are described. Methods include administration of luteolin to cells that exhibit dysregulation in PACT-mediated PKR activation. Methods can decrease or prevent excessive non-viral PACT-mediated PKR activation in a cell as may occur due to expression by the cell of a mutant PACT protein. Methods can decrease an abnormal prolonged stress response as may occur in the absence of a stress-inducing activity or agent.

Abstract: The present disclosure includes embodiments of a systems and methods of a community-based project platform for providing a collaborative project platform for projects. The embodiments of the methods may include determining one or more available projects for a first set of one or more users, based on a tag for each of the first set of one or more users and a type of the one or more available projects. In response to the determining of the one or more available projects for the first set of one or more users, the methods may additionally include, displaying the one or more available projects to the first set of one or more users.

Abstract: In various example embodiments, a system and method for versioning data in an unstructured data store are presented. The method includes generating a first record in the unstructured data store based on a version of a second record in the unstructured data store. The method further includes initializing a parent version identifier of the first record based on the version of the second record. The method further includes comparing the parent version identifier of the first record to a version identifier of the second record. The method further includes determining whether the first record is consistent based on the comparison.

Abstract: A method of inhibiting the growth or proliferation of ovarian cancer cells is provided. The method comprises contacting the ovarian cancer cells with an effective amount of 8-hydroxynaphthalene-1,3,6-trisulfonic acid (?-Stat), a salt of ?-Stat, a derivative of ?-Stat, or a salt of a derivative of ?-Stat. Also provided is a method of treating an ovarian cancer or inhibiting ovarian cancer cell growth or proliferation in a subject by administering to the subject a therapeutically effective amount of ?-Stat, a salt of ?-Stat, a derivative of ?-Stat, or a salt of a derivative of ?-Stat.

Abstract: In various example embodiments, a system and method for versioning data in an unstructured data store are presented. The method includes generating a first record in the unstructured data store based on a version of a second record in the unstructured data store. The method further includes initializing a parent version identifier of the first record based on the version of the second record. The method further includes comparing the parent version identifier of the first record to a version identifier of the second record. The method further includes determining whether the first record is consistent based on the comparison.

Abstract: Disclosed herein is synergistic herbal composition comprising extracts of herbal ingredients of Tribulus terrestris, Withania somnifera, Curculigo orchioides, Mucuna pruriens, Asparagus adscendens, Asteracantha longifolia, Asphaltum, and optionally the extracts of Piper longum and Anacyclus pyrethrum for the treatment of disorders associated with Male Sexual Dysfunction.

Abstract: Disclosed herein is synergistic herbal composition comprising extracts of herbal ingredients of Tribulus terrestris, Withania somnifera, Curculigo orchioides, Mucuna pruriens, Asparagus adscendens, Asteracantha longifolia, Asphaltum, and optionally the extracts of Piper longum and Anagclus pyrethrum for the treatment of disorders associated with Male Sexual Dysfunction.

Abstract: Disclosed herein is synergistic herbal composition comprising extracts of herbal ingredients of Tribulus terrestris, Withania somnifera, Curculigo orchioides, Mucuna pruriens, Asparagus adscendens, Asteracantha longifolia, Asphaltum, and optionally the extracts of Piper longum and Anacyclus pyrethrum for the treatment of disorders associated with Male Sexual Dysfunction.

Abstract: A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-iota, with respect to the control, indicates the presence of a glioma or meningioma in the subject. The present invention is based upon the discovery that PKC-iota levels are elevated during brain tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-iota. The invention also provides methods of treating gliomas and meningiomas by administering to the subject a compound that inhibits the expression of PKC-iota. The compound can be a small interfering RNA (siRNA) molecule.

Abstract: A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-iota, with respect to the control, indicates the presence of a glioma or meningioma in the subject. The present invention is based upon the discovery that PKC-iota levels are elevated during brain tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-iota. The invention also provides methods of treating gliomas and meningiomas by administering to the subject a compound that inhibits the expression of PKC-iota. The compound can be a small interfering RNA (siRNA) molecule.

Abstract: A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-iota, with respect to the control, indicates the presence of a glioma or meningioma in the subject. The present invention is based upon the discovery that PKC-iota levels are elevated during brain tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-iota. The invention also provides methods of treating gliomas and meningiomas by administering to the subject a compound that inhibits the expression of PKC-iota. The compound can be a small interfering RNA (siRNA) molecule.